Exploring a new target for treating neuropathic pain
Validation of a new large-pore channel as a novel target for neuropathic pain
This study is looking at a new way to help people with chronic nerve pain by exploring how certain immune cells in the spinal cord can make pain worse, and it aims to find safer treatments that don’t use opioids, so patients might have the chance to try out these new options.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10774593 on NIH RePORTER |
What this research studies
This research investigates a novel therapeutic target for neuropathic pain, a chronic condition affecting millions of Americans. The study focuses on understanding how microglia, a type of immune cell in the spinal cord, contribute to pain after nerve injury. By blocking the excessive release of ATP, a molecule that activates these cells, the research aims to develop safer pain management strategies that do not rely on opioids. Patients may be involved in trials assessing new treatments that could alleviate their chronic pain.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults suffering from chronic neuropathic pain, particularly those who have not found relief with current pain management options.
Not a fit: Patients with acute pain conditions or those who do not experience neuropathic pain may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective treatments for neuropathic pain, reducing reliance on opioids.
How similar studies have performed: Previous research has shown promise in targeting microglial activation for pain management, suggesting potential success for this novel approach.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Qiu, Zhaozhu — Johns Hopkins University
- Study coordinator: Qiu, Zhaozhu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.